ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Dipti Patel-Donnelly, MD

VCS Physicians

Dipti Patel-Donnelly, MD Headshot

Our understanding of the mechanisms and driving mutations of cancer are rapidly evolving. We use our medical knowledge, judgement, and vast experience to offer the most personalized, comprehensive, and compassionate care to guide every person through this challenging journey together.

Work and Credentials:

Primary Location

Fairfax Office

Position

Medical Oncologist

Board Certification

Medical Oncology, Hematology

Fellowship

Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Massachusetts General Hospital Medical Oncology and Hematology

Internship

Mount Sinai School of Medicine

Residency

Mount Sinai School of Medicine

Medical School

Mount Sinai School of Medicine

College

Binghamton University

Dipti Patel-Donnelly, MD

Oncologist and Assistant Professor of Oncology at Johns Hopkins University

Dr. Patel-Donnelly is dual board-certified in medical oncology and hematology. She completed her fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Massachusetts General Hospital at Harvard Medical School. Dr. Patel-Donnelly received her Doctorate of Medicine and completed her Internal Medicine Internship and Residency from the Mount Sinai School of Medicine in New York, New York, and she is a magna cum laude graduate in biochemistry with honors and independent research from Binghamton University in Binghamton, New York.

Dr. Patel-Donnelly is the President of Virginia Cancer Specialists and has played an active role in the local and medical communities. Dr. Patel-Donnelly holds memberships and appointments in multiple organizations. Dr. Patel-Donnelly is currently an Assistant Professor, in the Department of Oncology at Johns Hopkins University. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology, and the Medical Society of Virginia. Focusing on a special interest in hematologic malignancies, brain tumors, and stem cell transplant, Dr. Patel-Donnelly has become highly involved in local tumor boards and has served as Section Chief of Hematology/Oncology at Inova Fairfax Hospital and has held a Hematology/Oncology Faculty Clerkship appointment at Virginia Commonwealth University. Dr. Patel-Donnelly has also received multiple awards and honors which include the Harvard Partners in Excellence Award, Leukemia and Lymphoma Society’s “Relentless for a Cure” award, Excellence in Teaching Awards, National Institutes of Health Research Fellowship, NASE Achievement Scholarship, and Distinguished Honors and Independent Research in Biochemistry. Dr. Patel-Donnelly has been consistently named as a Top Doctor in publications such as Northern Virginia Magazine and Washingtonian magazine. Additionally, she has been listed as a “Castle Connolly Mid-Atlantic Top Doctor and a Washington Post Super Doctor”. Dr. Patel-Donnelly is a published author and has spoken both at local educational events and at national and local news interviews.

Dr. Patel-Donnelly is a member of several, prestigious, national committees. She is Chairwoman of the highly-selective, national panel tasked with writing/selecting Oncology Board questions for the American Board of Internal Medicine, which certifies that medical oncologists have a competent fund of knowledge to be board-certified and practice. She has also been selected to serve on the American Society of Clinical Oncology (ASCO) Leukemia Guideline Committee, which reviews current research evidence and makes uniform guidelines on treating leukemia.

Dr. Patel-Donnelly lives in Northern Virginia with her husband and two children. She enjoys spending time with her family, cooking, running, traveling, and reading.

 


 



Practice Blog

August 11, 2021

MMRF Team for Cures 5K Walk/Run on October 3, 2021 - Dipti Patel-Donnelly, MD

Read More
April 1, 2021

DC Blood Cancer Conference April 17, 2021 - Dipti Patel-Donnelly, MD

Read More

Physician Publications

December 6, 2020

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Read More
December 6, 2020

Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma

Read More
August 1, 2019

Entospletinib Monotherapy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Previously Treated With B-cell Receptor Inhibitors: Results of a Phase 2 Study

Read More

More Publications by Dipti Patel-Donnelly, MD

January 20, 2019

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline

Read More
January 11, 2019

Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

Read More
January 1, 2019

An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Read More
December 3, 2018

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline

Read More
August 18, 2018

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.

Read More
December 28, 2017

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Read More
April 1, 2017

WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY.

Read More
January 16, 2014

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Read More
June 2, 2013

Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).

Read More
November 15, 2012

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Read More
December 11, 2011

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Read More
October 20, 2009

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

Read More
January 1, 2003

The dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy

Read More

Clinical Trials (3)

Clinical Trial 11282

A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkins Lymphoma and CD30-expressing Peripheral T-Cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Therapy


Clinical Trial 17 058

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy (BBI-DSP7888-201G)


Clinical Trial 11-282

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above